

Platelet Factor 4 Complexed to Heparin Is the Target for Heparin-Induced Thrombocytopenia

Thrombosis and Haemostasis

68, 095-096

DOI: 10.1055/s-0038-1656329

Citation Report

#	ARTICLE	IF	CITATIONS
1	Heparin-associated Thrombocytopenia: No Association of Immune Response with HLA. <i>Vox Sanguinis</i> , 1993, 65, 151-153.	0.7	16
2	Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. <i>British Journal of Haematology</i> , 1993, 84, 711-716.	1.2	86
3	Mechanisms of Drug-Induced Immunologically Mediated Cytopenias. <i>Transfusion Medicine Reviews</i> , 1993, 7, 215-229.	0.9	43
4	Laboratory Investigation of Drug-Induced Immune Thrombocytopenias. <i>Transfusion Medicine Reviews</i> , 1993, 7, 275-287.	0.9	27
5	Drugs affecting blood coagulation and hemostasis. <i>Side Effects of Drugs Annual</i> , 1993, , 407-412.	0.6	0
6	Laboratory Monitoring of New Antithrombotic Drugs. <i>Clinics in Laboratory Medicine</i> , 1994, 14, 825-846.	0.7	7
7	Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. <i>Blood</i> , 1994, 83, 3232-3239.	0.6	365
8	Pentosan-induced thrombocytopenia: support for an immune complex mechanism. <i>British Journal of Haematology</i> , 1994, 88, 803-808.	1.2	38
9	Heparin-induced thrombocytopenia and antithrombotic therapy. <i>Lancet</i> , The, 1994, 344, 1296.	6.3	21
10	Autoimmune Thrombocytopenia Purpura. <i>BioDrugs</i> , 1994, 1, 348-357.	0.7	4
11	Drugs affecting blood coagulation and fibrinolysis. <i>Side Effects of Drugs Annual</i> , 1994, , 366-369.	0.6	0
12	Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. <i>Chest</i> , 1995, 108, 258S-275S.	0.4	396
13	Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. <i>British Journal of Haematology</i> , 1995, 91, 173-177.	1.2	55
14	Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). <i>British Journal of Haematology</i> , 1995, 91, 736-738.	1.2	48
15	Single amino acid mutation of FC β 3 receptor is associated with the development of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1995, 91, 761-766.	1.2	114
16	Annotation. <i>British Journal of Haematology</i> , 1995, 89, 431-439.	1.2	254
17	Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 1995, 50, 20-25.	2.0	118
18	Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance. <i>American Journal of Hematology</i> , 1995, 50, 292-295.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 20, 271-296.	2.0	22
20	State-of-the-Art Review: Usefulness of Laboratory Techniques for Evaluating Antithrombotic Efficacy of New Therapeutic Strategies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1995, 1, 243-259.	0.7	3
21	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. <i>New England Journal of Medicine</i> , 1995, 332, 1330-1336.	13.9	2,664
22	COAGULATION DISORDERS IN CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1996, 10, 457-484.	0.9	80
23	A 14-year study of heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 1996, 101, 502-507.	0.6	872
24	Platelet binding of IgG from patients with heparin-induced thrombocytopenia. <i>Translational Research</i> , 1996, 127, 435-442.	2.4	49
25	Heparin-induced thrombocytopenia in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1996, 28, 82-85.	2.1	174
26	Heparin-induced thrombocytopenia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1996, 10, 521-530.	0.6	40
27	Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. <i>Blood</i> , 1996, 88, 410-416.	0.6	240
28	Heparin as a cause of thrombus progression. <i>European Journal of Pediatrics</i> , 1996, 155, 11-14.	1.3	41
29	Pentosan polysulfate-induced thrombocytopenia: a case diagnosed with an ELISA test used for heparin-induced thrombocytopenia. <i>Annals of Hematology</i> , 1996, 73, 51-52.	0.8	7
30	Heparin-induced thrombocytopenia: What the serologists have taught us. <i>Translational Research</i> , 1996, 128, 346-348.	2.4	10
31	Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. <i>Translational Research</i> , 1996, 128, 376-383.	2.4	173
32	Heparin-induced thrombocytopenia: Understanding improves but questions remain. <i>Translational Research</i> , 1996, 127, 418-419.	2.4	12
33	Heparin induced thrombocytopenia. <i>European Journal of Vascular and Endovascular Surgery</i> , 1996, 11, 260-269.	0.8	13
34	Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 1996, 10, 249-258.	0.9	104
35	Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. , 1996, 52, 90-95.		108
36	Heparin-induced thrombocytopenia: an under-diagnosed syndrome?. <i>Platelets</i> , 1997, 8, 65-82.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Heparin-Induced Thrombocytopenia: Prevalence in a Large Cohort of Patients and Confirmed Role of PF4/Heparin Complex as the Main Antigen for Antibodies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997, 3, 203-209.	0.7	4
39	Heparin-associated Thrombocytopenia and Thrombosis. <i>Anesthesiology</i> , 1997, 87, 667-675.	1.3	44
40	Heparin-Induced Thrombocytopenia. <i>Drug Safety</i> , 1997, 17, 325-341.	1.4	91
41	Danaparoid. <i>Drugs</i> , 1997, 54, 903-924.	4.9	100
42	Cytokines, Adhesion Molecules, Antiendothelial Cell Autoantibodies and Vascular Disease. <i>Cardiovascular Pathology</i> , 1997, 6, 61-78.	0.7	12
43	Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient. <i>Surgery</i> , 1997, 121, 419-424.	1.0	18
44	EFFICACY OF PENTASACCHARIDE IN A DOG MODEL OF HEMODIALYSIS. <i>Thrombosis Research</i> , 1997, 88, 159-170.	0.8	7
45	Effective Anticoagulation by Argatroban During Coronary Stent Implantation in a Patient with Heparin-Induced Thrombocytopenia. <i>Thrombosis Research</i> , 1997, 88, 499-502.	0.8	8
46	Failure of low dosage thrombolytic therapy with streptokinase to treat heparin-induced thrombocytopenic-thrombotic syndrome. <i>International Journal of Cardiology</i> , 1997, 62, 87-89.	0.8	2
47	Management of Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997, 3, S53-S63.	0.7	9
48	The need for improved diagnosis of heparin-induced thrombocytopenia. <i>Translational Research</i> , 1997, 130, 242-244.	2.4	2
49	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the FcγR1a low responder (his131) gene in patients with heparin-induced thrombocytopenia. <i>Translational Research</i> , 1997, 130, 278-284.	2.4	88
50	Erfolgreiche Behandlung einer Heparin-induzierten Thrombo-zytopenie Typ II im Kindesalter mit rekombinantem Hirudin. <i>Monatsschrift Fur Kinderheilkunde</i> , 1997, 145, 606-612.	0.1	28
51	Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo : generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. <i>Clinical and Experimental Immunology</i> , 1997, 108, 333-339.	1.1	31
52	Characterization of the humoral immune response in heparin-induced thrombocytopenia. , 1997, 54, 196-201.		103
53	High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. <i>Journal of Clinical Immunology</i> , 1998, 18, 330-334.	2.0	32
54	12 Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. <i>Best Practice and Research: Clinical Haematology</i> , 1998, 11, 447-460.	1.1	12
55	13 Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. <i>Best Practice and Research: Clinical Haematology</i> , 1998, 11, 461-474.	1.1	7

#	ARTICLE	IF	CITATIONS
56	Heparin-Induced Thrombocytopenia and Thrombosis. Journal of the American College of Surgeons, 1998, 186, 76-91.	0.2	27
57	Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. , 1998, 58, 24-30.		45
58	Heparininduzierte Thrombozytopenie vom Typ II bei einem Patienten mit biventrikulärem Unterstützungssystem. Zeitschrift Fur Herz-, Thorax- Und Gefasschirurgie, 1998, 12, 140-143.	0.0	0
60	Heparin-induced thrombocytopenia and thrombosis. Clinical Reviews in Allergy and Immunology, 1998, 16, 237-247.	2.9	20
61	Low-molecular-weight heparin-induced skin necrosis. Annals of Hematology, 1998, 77, 127-130.	0.8	11
62	Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85â€ƒkD form of CD36 as a target antigen. British Journal of Haematology, 1998, 103, 849-857.	1.2	37
64	Les thrombopÃ©nies induites par l'hÃ©parine Physiopathologie et thÃ©rapeutique Conduite Ã tenir en chirurgie cardiaque. IRBM News, 1998, 20, 42-46.	0.0	0
65	Indications for therapeutic platelet transfusions. Blood Reviews, 1998, 12, 227-233.	2.8	11
66	Platelet Receptors for the Complement Component C1q: Implications for Hemostasis and Thrombosis. Immunobiology, 1998, 199, 239-249.	0.8	52
68	Peptide LSARLAF Activates Î±IIbÎ²3 on Resting Platelets and Causes Resting Platelet Aggregate Formation Without Platelet Shape Change. Thrombosis Research, 1998, 89, 31-40.	0.8	18
69	Platelet Count, Anti-Heparin/Platelet Factor 4 Antibodies and Tissue Factor Pathway Inhibitor Plasma Antigen Level in Chronic Dialysis. Thrombosis Research, 1998, 89, 115-122.	0.8	57
70	Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia. Annals of Thoracic Surgery, 1998, 66, 567-569.	0.7	17
71	Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 1998, 31, 1449-1459.	1.2	198
72	Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. Journal of Vascular Surgery, 1998, 27, 309-316.	0.6	48
73	Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies. American Heart Journal, 1998, 135, S152-S159.	1.2	24
74	The incidence of heparin-induced antibodies in patients undergoing vascular surgery: A prospective study. Journal of Vascular Surgery, 1998, 28, 439-445.	0.6	23
75	HEPARIN-INDUCED THROMBOCYTOPENIA, PARADOXICAL THROMBOEMBOLISM, AND OTHER SIDE EFFECTS OF HEPARIN THERAPY. Medical Clinics of North America, 1998, 82, 635-658.	1.1	83
76	Two populations of endothelial cell antibodies cross-react with heparin. Lupus, 1998, 7, 86-94.	0.8	24

#	ARTICLE	IF	CITATIONS
77	Anti-heparin antibodies: part of the repertoire of anti-endothelial cell antibodies (AECA). <i>Lupus</i> , 1998, 7, 68-72.	0.8	14
78	The First Report of Successful Carotid Stent Implant Using Argatroban Anticoagulation in a Patient with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. <i>Angiology</i> , 1998, 49, 61-67.	0.8	22
79	Antibody-mediated thrombosis: Relation to the antiphospholipid syndrome. <i>Lupus</i> , 1998, 7, 63-66.	0.8	7
80	Heparin and Low-Molecular-Weight Heparin. <i>Chest</i> , 1998, 114, 489S-510S.	0.4	679
81	Skin Necrosis at the Injection Site Induced by Low-Molecular-Weight Heparin: Case Report and Review. <i>Dermatology</i> , 1998, 196, 264-265.	0.9	24
82	Heparin-induced thrombocytopenia. <i>Postgraduate Medicine</i> , 1998, 103, 169-178.	0.9	21
83	Prevalence of Heparin-Induced PF4-Heparin Antibodies in Hemodialysis Patients. <i>Nephron</i> , 1998, 79, 245-246.	0.9	42
84	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. <i>Blood</i> , 1998, 91, 549-554.	0.6	99
85	Antibodies From Patients With Heparin-Induced Thrombocytopenia/Thrombosis Recognize Different Epitopes on Heparin: Platelet Factor 4. <i>Blood</i> , 1998, 91, 916-922.	0.6	110
86	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the Fc γ RIIIa-R-H131 Polymorphism. <i>Blood</i> , 1998, 92, 1526-1531.	0.6	176
87	Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia. <i>Blood</i> , 1998, 92, 3250-3259.	0.6	125
88	Heparin-induced Thrombocytopenia: Towards Consensus. <i>Thrombosis and Haemostasis</i> , 1998, 79, 1-7.	1.8	595
89	Heparin-Induced Thrombocytopenia: Historical Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S2-S6.	0.7	5
90	First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA. <i>Thrombosis and Haemostasis</i> , 1999, 81, 625-629.	1.8	161
91	Heparin-Induced Thrombocytopenic Potential of GAG and Non-GAG-Based Antithrombotic Agents. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S56-S62.	0.7	10
92	Generation and Pathogenicity of Anti-Platelet Factor 4 Antibodies: Diagnostic Implications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S28-S31.	0.7	14
93	Vascular Damage Correlates between Heparin-Induced Thrombocytopenia and the Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S76-S84.	0.7	12
94	Complexes of Heparin and Platelet Factor 4 Specifically Stimulate T Cells From Patients With Heparin-Induced Thrombocytopenia/Thrombosis. <i>Blood</i> , 1999, 94, 208-215.	0.6	48

#	ARTICLE	IF	CITATIONS
95	Antibodies to Platelet Factor 4â€“Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin. <i>Circulation</i> , 1999, 99, 2530-2536.	1.6	325
97	Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 1999, 99, 73-80.	1.6	505
98	Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 259-266.	0.7	69
99	HEPARIN-INDUCED THROMBOCYTOPENIA: A Ten-Year Retrospective. <i>Annual Review of Medicine</i> , 1999, 50, 129-147.	5.0	128
100	Platelet microparticles: a wide-angle perspective. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 30, 111-142.	2.0	275
101	Association of heparinâ€“induced skin lesions, intracutaneous tests, and heparinâ€“induced IgG. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 473-477.	2.7	66
102	Heparin-induced thrombocytopenia. <i>Blood Reviews</i> , 1999, 13, 1-7.	2.8	17
103	Further characterization of antibody and antigen in heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1999, 107, 303-309.	1.2	52
106	Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy</i> , 1999, 19, 181-195.	1.2	49
107	Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). <i>Journal of Immunological Methods</i> , 1999, 222, 93-99.	0.6	16
108	PERIOPERATIVE ANTICOAGULATION AND THROMBOLYSIS IN CONGENITAL AND ACQUIRED COAGULOPATHIES. <i>Anesthesiology Clinics</i> , 1999, 17, 923-958.	1.4	4
109	Ventricular thrombus and subarachnoid bleeding during support with ventricular assist devices. <i>Annals of Thoracic Surgery</i> , 1999, 67, 1778-1780.	0.7	11
110	Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. <i>American Journal of Medicine</i> , 1999, 106, 660-669.	0.6	36
111	Laboratory Diagnosis of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S21-S27.	0.7	36
112	Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S32-S37.	0.7	16
113	Efficacy and Safety of Danaparoid Sodium (ORG 10172) in Critically Ill Patients With Heparin-Associated Thrombocytopenia. <i>Chest</i> , 1999, 115, 1616-1620.	0.4	83
114	Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia. <i>Hematology</i> , 1999, 4, 367-372.	0.7	11
115	Neurologic complications in immune-mediated heparin-induced thrombocytopenia. <i>Neurology</i> , 2000, 54, 1240-1245.	1.5	58

#	ARTICLE	IF	CITATIONS
116	ET gets HIT – thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 663-667.	0.5	17
117	Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2000, 109, 182-186.	1.2	36
118	Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. <i>British Journal of Haematology</i> , 2000, 109, 336-341.	1.2	66
119	Heparin-induced skin necrosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1315-1316.	1.1	13
120	Heparin-induced thrombocytopenia. <i>Journal of Vascular Nursing</i> , 2000, 18, 54-58.	0.2	0
121	Heparin induced thrombocytopenia and thrombosis. <i>Progress in Cardiovascular Diseases</i> , 2000, 42, 247-260.	1.6	19
122	Evaluation and Management of Drug-Induced Thrombocytopenia in the Acutely Ill Patient. <i>Pharmacotherapy</i> , 2000, 20, 292-307.	1.2	66
123	Key references: anticoagulants and coagulation monitoring. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 69-76.	1.0	0
124	Heparin-induced thrombocytopenia and its treatment. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 29-35.	1.0	16
125	Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 13-20.	1.0	66
126	Laboratory testing for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 35-45.	1.0	58
127	Pulmonary embolus after coronary artery bypass surgery: A review of the literature. <i>Clinical Cardiology</i> , 2000, 23, 637-644.	0.7	75
128	Complications during Inpatient Thrombosis Prophylaxis – Experience from 40 Patients with Heparin-Induced Thrombocytopenia Type II (HIT II). <i>European Journal of Trauma and Emergency Surgery</i> , 2000, 26, 226-232.	0.3	0
129	Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. <i>Blood</i> , 2000, 95, 1533-1540.	0.6	112
130	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 188-194.	0.6	190
131	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-1708.	0.6	976
132	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. <i>Blood</i> , 2000, 96, 2373-2378.	0.6	220
133	Characteristics of Heparin-Induced Platelet Aggregates in Chronic Hemodialysis with Long-Term Heparin Use. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 249-257.	0.5	5

#	ARTICLE	IF	CITATIONS
134	State-of-the-Art Review : Heparin-Induced Thrombocytopenia: A Critical Risk/Benefit Analysis of Patients in Intensive Care Treated With R-Hirudin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000, 6, 151-156.	0.7	4
135	Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia. <i>Platelets</i> , 2000, 11, 23-27.	1.1	14
136	Endovascular Repair of an Extracranial Internal Carotid Artery Aneurysm Complicated by Heparin-Induced Thrombocytopenia and Thrombosis. <i>Journal of Endovascular Therapy</i> , 2000, 7, 353-358.	0.8	25
137	Antiphospholipid Syndrome and Heparin-induced Thrombocytopenia: Update on Similarities and Differences. <i>Journal of Autoimmunity</i> , 2000, 15, 265-268.	3.0	25
138	In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. <i>Journal of Clinical Anesthesia</i> , 2000, 12, 324-327.	0.7	26
139	A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II. <i>Thrombosis Research</i> , 2000, 99, 325-334.	0.8	34
140	Human Anti-heparin-Platelet Factor 4 Antibodies Are Capable of Activating Primate Platelets. <i>Thrombosis Research</i> , 2000, 100, 47-54.	0.8	3
141	Very Low Platelet Counts in Post-transfusion Purpura Falsely Diagnosed as Heparin-induced Thrombocytopenia. <i>Thrombosis Research</i> , 2000, 100, 115-125.	0.8	70
142	A Prospective Study on the Incidence and Clinical Relevance of Heparin-Induced Antibodies in Patients after Vascular Surgery. <i>Thrombosis Research</i> , 2000, 97, 387-393.	0.8	63
143	Heparin-Induced Thrombocytopenia. <i>Drugs and Aging</i> , 2000, 16, 351-364.	1.3	19
144	Temporal Aspects of Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2001, 344, 1286-1292.	13.9	925
145	Identification of T cells responding to a self-protein modified by an external agent. <i>Human Immunology</i> , 2001, 62, 113-124.	1.2	18
146	Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. <i>Annals of Thoracic Surgery</i> , 2001, 71, 678-683.	0.7	60
147	Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. <i>Annals of Thoracic Surgery</i> , 2001, 71, 1920-1924.	0.7	34
148	BLEEDING AND THROMBOTIC COMPLICATIONS IN CRITICALLY ILL PATIENTS WITH CANCER. <i>Critical Care Clinics</i> , 2001, 17, 599-622.	1.0	25
149	Delayed thrombocytopenia following abciximab therapy. <i>International Journal of Cardiovascular Interventions</i> , 2001, 4, 151-155.	0.5	12
150	Improved Laboratory Confirmation of Heparin-Induced Thrombocytopenia Type II. <i>American Journal of Clinical Pathology</i> , 2001, 115, 432-438.	0.4	14
151	The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 511-520.	0.5	13

#	ARTICLE	IF	CITATIONS
152	Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fc γ RIIA. <i>Blood</i> , 2001, 98, 2442-2447.	0.6	193
153	Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. <i>Blood</i> , 2001, 97, 3300-3302.	0.6	191
154	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. <i>Annals of Internal Medicine</i> , 2001, 135, 502.	2.0	429
155	Mechanism and Clinical Presentation of Heparin-Induced Thrombocytopenia. <i>Hemodialysis International</i> , 2001, 5, 74-80.	0.4	3
156	Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. <i>Current Cardiology Reports</i> , 2001, 3, 362-370.	1.3	9
157	Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. <i>British Journal of Haematology</i> , 2001, 112, 69-75.	1.2	13
158	Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2001, 113, 886-890.	1.2	92
159	Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 468-472.	0.7	26
160	Heparin induced thrombocytopenia: prevalence in India. <i>American Journal of Hematology</i> , 2001, 68, 216-217.	2.0	2
161	Association of eptifibatid and acute profound thrombocytopenia. <i>American Journal of Cardiology</i> , 2001, 88, 428-431.	0.7	62
162	Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex. <i>Translational Research</i> , 2001, 137, 408-413.	2.4	19
163	Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. <i>Translational Research</i> , 2001, 138, 22-31.	2.4	129
164	Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 331-335.	0.4	41
165	DRUG-INDUCED AND DRUG-DEPENDENT IMMUNE THROMBOCYTOPENIAS. <i>Reviews in Clinical and Experimental Hematology</i> , 2001, 5, 166-200.	0.1	49
166	Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. <i>European Journal of Haematology</i> , 2001, 66, 195-199.	1.1	10
167	Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. <i>Journal of Clinical Pathology</i> , 2001, 54, 272-274.	1.0	62
168	Guide to Anticoagulant Therapy: Heparin. <i>Circulation</i> , 2001, 103, 2994-3018.	1.6	451
169	Guide to Anticoagulant Therapy: Heparin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, E9-9.	1.1	50

#	ARTICLE	IF	CITATIONS
170	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. <i>Chest</i> , 2001, 119, 64S-94S.	0.4	1,275
171	Use of a Low-Molecular-Weight Heparinoid (Danaparoid Sodium) for Continuous Renal Replacement Therapy in Intensive Care Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 300-304.	0.7	34
172	Heparin-Induced Thrombocytopenia-Associated Thrombosis in Pediatric Intensive Care Patients. <i>Pediatrics</i> , 2002, 109, e10-e10.	1.0	106
173	Development of a High-Pressure Liquid Chromatography Method for Diagnosis of Heparin-Induced Thrombocytopenia. <i>American Journal of Clinical Pathology</i> , 2002, 117, 900-904.	0.4	10
174	Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. <i>International Immunology</i> , 2002, 14, 121-129.	1.8	118
175	Risk Factors and Long-term Follow-up of Patients with the Immune Type of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 347-352.	0.7	11
176	Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. <i>Current Opinion in Hematology</i> , 2002, 9, 395-400.	1.2	21
177	Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. <i>Blood</i> , 2002, 99, 1230-1236.	0.6	117
178	Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2002, 105, 117-123.	0.8	44
179	Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. <i>Thrombosis Research</i> , 2002, 108, 49-55.	0.8	31
180	Heparin-induced thrombocytopenia: a common complication in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 1283-1289.	0.3	46
181	Pathogenesis of heparin-induced thrombocytopenia and thrombosis. <i>Autoimmunity Reviews</i> , 2002, 1, 125-132.	2.5	33
182	Allergies aux héparines. <i>Revue Française D'allergologie Et D'immunologie Clinique</i> , 2002, 42, 97-103.	0.1	3
183	Effects of Î²2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , 2002, 46, 3283-3289.	6.7	20
184	Heparin-induced thrombocytopenia: Molecular pathogenesis. <i>International Journal of Hematology</i> , 2002, 76, 346-351.	0.7	4
185	The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. <i>British Journal of Haematology</i> , 2002, 116, 887-891.	1.2	85
186	Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. <i>Journal of Internal Medicine</i> , 2002, 252, 149-154.	2.7	61
187	Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. <i>British Journal of Haematology</i> , 2002, 118, 1137-1142.	1.2	111

#	ARTICLE	IF	CITATIONS
188	Mechanisms of Action of IVIg: Physiology of Fc Receptors. <i>Vox Sanguinis</i> , 2002, 83, 57-63.	0.7	5
189	Heparin-induced thrombocytopenia: an overview. <i>Blood Reviews</i> , 2002, 16, 77-80.	2.8	94
190	Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 351-354.	0.7	17
191	HEPARIN-INDUCED THROMBOCYTOPENIA IN DIALYSIS: The Pathophysiology of Immune-mediated Heparin-induced Thrombocytopenia. <i>Seminars in Dialysis</i> , 2003, 16, 54-60.	0.7	48
192	Heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1471-1478.	1.9	213
193	Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia?. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1844-1845.	1.9	21
194	Heparin-induced thrombocytopenia: pathogenesis and management. <i>British Journal of Haematology</i> , 2003, 121, 535-555.	1.2	492
195	Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 259-282.	0.9	16
196	Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia. <i>Drug Safety</i> , 2003, 26, 625-641.	1.4	28
197	Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 2003, 114, 528-536.	0.6	72
198	A positive in vitro assay is required to diagnose heparin-induced thrombocytopenia. <i>Medical Clinics of North America</i> , 2003, 87, 1215-1224.	1.1	4
199	HIT/HITT and alternative anticoagulation: current concepts. <i>British Journal of Anaesthesia</i> , 2003, 90, 676-685.	1.5	40
200	Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 341-346.	0.7	3
201	On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran®) in Patients With Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 25-32.	0.7	12
202	Laboratory Diagnosis of Heparin-Induced Thrombocytopenia and Monitoring of Alternative Anticoagulants. <i>Vaccine Journal</i> , 2003, 10, 731-740.	3.2	26
203	Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 497-519.	0.9	127
204	Platelet Function and Immune Response. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, S19-S23.	0.3	8
205	Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia. , 2004, 93, 61-82.		7

#	ARTICLE	IF	CITATIONS
206	Platelet activation induced by human antibodies to interleukin-8. <i>Blood</i> , 2003, 101, 1419-1421.	0.6	91
207	The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. <i>Blood</i> , 2003, 101, 2955-2959.	0.6	271
208	Laboratory Methods for Heparin-Induced Thrombocytopenia. , 2004, 93, 83-94.		1
209	Hypercoagulability as a Cause of Stroke in Adults. <i>Southern Medical Journal</i> , 2003, 96, 350-353.	0.3	16
210	Anti-Heparin-Platelet Factor 4 Antibody is a Risk Factor for Vascular Access Obstruction in Patients Undergoing Hemodialysis. <i>Journal of Korean Medical Science</i> , 2003, 18, 69.	1.1	9
211	Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. <i>Thrombosis and Haemostasis</i> , 2004, 91, 276-282.	1.8	50
212	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. <i>Chest</i> , 2004, 126, 311S-337S.	0.4	766
213	Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. <i>Neurology</i> , 2004, 62, 657-659.	1.5	39
215	Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2004, 76, 69-73.	2.0	32
216	Heparin is much more than just an anticoagulant. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2004, 18, 93-100.	0.6	21
218	Heparin-Induced Thrombocytopenia. <i>International Anesthesiology Clinics</i> , 2004, 42, 27-43.	0.3	19
219	Treatment of Heparin-Induced Thrombocytopenia. <i>Archives of Internal Medicine</i> , 2004, 164, 361.	4.3	184
220	Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 385-391.	1.2	29
221	New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2005, 127, 35S-45S.	0.4	145
222	Heparin-induced thrombocytopenia in the pediatric intensive care unit population. <i>Pediatric Critical Care Medicine</i> , 2005, 6, 216-219.	0.2	17
223	The Pathophysiology of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2005, 127, 9S-20S.	0.4	96
224	Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2168-2175.	1.9	53
225	Heparin-induced thrombocytopenia antibody and the pathogenesis of thrombotic microangiopathy after stem cell transplantation. <i>Clinical Transplantation</i> , 2005, 19, 418-422.	0.8	5

#	ARTICLE	IF	CITATIONS
226	Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states. <i>International Journal of Dermatology</i> , 2005, 44, 964-966.	0.5	15
227	Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. <i>Hemodialysis International</i> , 2005, 9, S2-S7.	0.4	28
228	A rare case of HITTS following prophylactic LMWH therapy in a blunt trauma victim. <i>Injury</i> , 2005, 36, 347-351.	0.7	1
229	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. <i>Translational Research</i> , 2005, 146, 341-346.	2.4	261
230	Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. <i>Journal of Clinical Laboratory Analysis</i> , 2005, 19, 189-195.	0.9	35
231	Thrombocytopenic conditions—autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS. <i>American Journal of Hematology</i> , 2005, 80, 232-242.	2.0	38
232	Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 11-19.	1.0	33
233	Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. <i>Thrombosis Journal</i> , 2005, 3, 4.	0.9	12
235	Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 27, 138-149.	0.6	22
236	Low-molecular-weight heparin-associated fat necrosis of the breast. <i>Age and Ageing</i> , 2005, 34, 193-194.	0.7	7
237	Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. <i>Neurology</i> , 2005, 64, 1285-1287.	1.5	24
238	Heparin-Induced Thrombocytopenia Complicating Support by the Berlin Heart. <i>ASAIO Journal</i> , 2005, 51, 820-825.	0.9	20
239	Mechanistic basis of heparin-induced thrombocytopenia. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2005, 17, 73-79.	0.4	29
240	Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2005, 17, 85-96.	0.4	25
241	Heparin-Induced Thrombocytopenia: An Iceberg Rising. <i>Mayo Clinic Proceedings</i> , 2005, 80, 988-990.	1.4	19
242	Association of Heparin-Dependent Antibodies and Adverse Outcomes in Hemodialysis Patients: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2005, 80, 995-1000.	1.4	62
243	Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2005, 105, 131-138.	0.6	272
244	Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopenia: present and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 81-89.	0.9	8

#	ARTICLE	IF	CITATIONS
245	Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2006, 355, 809-817.	13.9	560
246	Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. <i>Thrombosis Research</i> , 2006, 118, 123-135.	0.8	79
247	Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. <i>Blood</i> , 2006, 107, 2346-2353.	0.6	234
248	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. <i>Blood</i> , 2006, 108, 2937-2941.	0.6	259
250	ThrombopÃ©nies et thromboses induites par l'hÃ©parine: Un syndrome clinico-biologique sÃ©vÃ©re. <i>Revue Francophone Des Laboratoires</i> , 2006, 2006, 49-58.	0.0	1
251	Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [¹⁴ C]-serotonin release assay. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1136-1139.	1.9	21
253	Catastrophic thromboses and severe thrombocytopenia during heparin therapy in a patient with anti-phospholipid syndrome. <i>Clinical Rheumatology</i> , 2006, 25, 426-429.	1.0	7
254	Diagnosis and management of heparin-induced thrombocytopenia. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, S123-S134.	0.7	11
255	Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. <i>European Journal of Haematology</i> , 2006, 76, 420-426.	1.1	162
256	Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Transfusion Medicine Reviews</i> , 2006, 20, 259-272.	0.9	142
258	Heparin-induced thrombocytopenia and thrombosis. <i>American Journal of Hematology</i> , 2006, 81, 36-44.	2.0	68
259	HIT: Lessons Learned. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 50-57.	0.5	25
260	Heparin-Induced Thrombocytopenia: Frequency and Pathogenesis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 37-45.	0.5	26
261	Heparin-Induced Thrombocytopenia: A Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 803-809.	1.5	145
262	Disseminated intravascular clotting associated with Fc-receptor IIa-mediated platelet activation in a patient with endocarditis after aortic valve replacement. <i>British Journal of Anaesthesia</i> , 2006, 97, 630-633.	1.5	4
263	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2386-2393.	1.1	156
264	A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 5471-5480.	3.2	92
265	Incidence of AntiheparinÃ©Platelet Factor 4 Antibodies and Heparin-Induced Thrombocytopenia in Turkish Patients Undergoing Cardiac Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 279-284.	0.7	4

#	ARTICLE	IF	CITATIONS
266	Hgh prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. <i>Lupus</i> , 2007, 16, 79-83.	0.8	33
267	Heparin-Induced Thrombocytopenia. <i>Journal of Infusion Nursing</i> , 2007, 30, 232-240.	1.2	5
268	Endothelial cell damage in heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 317-320.	0.5	15
269	Heparin-Induced Thrombocytopenia Type II: A Serious Hazard in Preemptive Renal Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2007, 39, 3481-3484.	0.3	11
270	Spontaneous superior sagittal sinus thrombosis secondary to type II heparin-induced thrombocytopenia presenting as an acute subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 890-895.	0.8	13
271	Drug-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 685-696.	0.9	128
273	Heparin-induced thrombocytopenia: Impact of bovine versus porcine heparin in HIT pathogenesis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3312.	3.0	12
274	Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2007, 82, 276-282.	2.0	6
275	Attempts to make sense of the antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1-4.	1.9	13
276	Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1666-1673.	1.9	224
277	Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 55-61.	1.0	35
278	A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 65-74.	1.1	22
279	Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. <i>Transfusion</i> , 2008, 48, 2128-2132.	0.8	55
280	Quantitative interpretation of optical density measurements using PF4-dependent enzyme immunoassays. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1304-1312.	1.9	333
281	An algorithm for resolving "indeterminate" test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1595-1597.	1.9	24
282	Heparin-induced thrombocytopenia " therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2160-2167.	1.9	68
283	Rivaroxaban " an oral, direct Factor Xa inhibitor " has potential for the management of patients with heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2008, 143, 92-99.	1.2	78
284	Chapter 45 Hematological diseases and stroke. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 93, 887-934.	1.0	1

#	ARTICLE	IF	CITATIONS
285	Lepirudin in the management of heparin-induced thrombocytopenia. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1131-1141.	1.5	7
286	The Relationship Between the Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia. Hematology/Oncology Clinics of North America, 2008, 22, 1-18.	0.9	27
287	Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. Journal of Vascular Surgery, 2008, 48, 377-381.	0.6	6
288	Serologic Results in >1000 Patients With Suspected Heparin-Induced Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 410-414.	0.7	11
289	Heparin induced thrombocytopenia with thrombosis: a two step process?. Hematology, 2008, 13, 181-182.	0.7	3
290	The Laboratory Diagnosis and Clinical Management of Patients with Heparin-Induced Thrombocytopenia: An Update. Seminars in Thrombosis and Hemostasis, 2008, 34, 086-096.	1.5	35
291	Heparin-induced thrombocytopenia: a historical perspective. Blood, 2008, 112, 2607-2616.	0.6	172
292	Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood, 2008, 112, 1091-1100.	0.6	71
293	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2008, 133, 340S-380S.	0.4	783
294	Urgent Cardiac Surgery in a Patient with a Remote History of Heparin-Induced Thrombocytopenia: Use of the Anti-PF4/Heparin ELISA Confirmatory Test. Anesthesia and Analgesia, 2008, 107, 379-381.	1.1	10
295	A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin. Blood Coagulation and Fibrinolysis, 2008, 19, 477-481.	0.5	6
296	The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thrombocytopenia and thrombosis caused by heparin flushes. Therapeutics and Clinical Risk Management, 2008, Volume 4, 653-657.	0.9	13
297	Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 428-434.	0.7	15
298	ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. Hematology American Society of Hematology Education Program, 2009, 2009, 250-252.	0.9	28
299	The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. Journal of Neurosurgery, 2009, 110, 50-57.	0.9	15
300	Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement. BMC Musculoskeletal Disorders, 2009, 10, 42.	0.8	4
301	Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2009, 7, 249-252.	1.9	21
302	Heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 9-12.	1.9	126

#	ARTICLE	IF	CITATIONS
303	Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. <i>Intensive Care Medicine</i> , 2009, 35, 1449-1453.	3.9	22
304	Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotypic antibodies. <i>Transfusion</i> , 2009, 49, 1812-1818.	0.8	4
305	Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1067-1069.	1.9	7
306	Immunoassays are not created equal. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1256-1259.	1.9	21
307	High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1416-1418.	1.9	11
308	Thrombin generation and heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1474-1481.	1.9	40
309	Heparin-induced thrombocytopenia: a renal perspective. <i>Nature Reviews Nephrology</i> , 2009, 5, 501-511.	4.1	51
310	Heparin-induced thrombocytopenia after implantation of a heparin-bonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management. <i>Journal of Vascular Surgery</i> , 2009, 49, 1037-1040.	0.6	20
311	Cell-derived microparticles in haemostasis and vascular medicine. <i>Thrombosis and Haemostasis</i> , 2009, 101, 439-451.	1.8	359
312	Thrombotic Thrombocytopenic Purpura and Heparin-Induced Thrombocytopenia: Two Unique Causes of Life-Threatening Thrombocytopenia. <i>Clinics in Laboratory Medicine</i> , 2009, 29, 321-338.	0.7	17
313	Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2009, 135, 1651-1664.	0.4	124
314	The temporal profile of the anti-PF4/heparin immune response. <i>Blood</i> , 2009, 113, 4970-4976.	0.6	109
315	Studies of the immune response in heparin-induced thrombocytopenia. <i>Blood</i> , 2009, 113, 4963-4969.	0.6	157
316	Treatment options in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2010, 17, 424-431.	1.2	11
317	Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2010, 116, 5021-5031.	0.6	134
318	Significance of quantitative measurement of heparin-induced platelet antibodies. <i>European Journal of Haematology</i> , 2010, 84, 169-174.	1.1	7
319	Heparin-induced thrombocytopenia: Current status and diagnostic challenges. <i>American Journal of Hematology</i> , 2010, 85, 700-706.	2.0	45
320	Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. <i>Transfusion</i> , 2010, 50, 32-39.	0.8	30

#	ARTICLE	IF	CITATIONS
321	Postoperative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocytopenia after cardiac surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 27-29.	1.9	30
322	Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 616-618.	1.9	27
323	Anti- PF4 /heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 504-512.	1.9	51
325	Heparin-induced thrombocytopenia/Thrombosis: a clinico-pathological review. <i>East African Medical Journal</i> , 2010, 86, .	0.0	2
326	Immunobiology of Heparin-Induced Thrombocytopenia. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 193-202.	0.7	4
327	In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 377-386.	0.7	17
328	Fondaparinux (Arixtra [®]), a Safe Alternative for the Treatment of Patients With Heparin-Induced Thrombocytopenia?. <i>Journal of Pharmacy Practice</i> , 2010, 23, 235-238.	0.5	9
329	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2605-2610.	1.1	55
330	Agents for the Treatment of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 755-775.	0.9	65
331	Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia. <i>Clinics in Chest Medicine</i> , 2010, 31, 691-706.	0.8	7
332	Review: Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 5-12.	0.7	7
333	Physiological changes in membrane-expressed platelet factor 4: Implications in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2010, 125, e143-e148.	0.8	9
334	Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. <i>Thrombosis Research</i> , 2010, 125, e234-e239.	0.8	40
335	Clinical characteristics and laboratory testing of patients with suspected HIT: A survey on current practice in 11 university hospitals in France. <i>Thrombosis Research</i> , 2010, 125, e294-e299.	0.8	9
336	Preoperative Heparin Therapy Causes Immune-Mediated Hypotension Upon Heparin Administration for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2010, 24, 69-72.	0.6	4
337	Fondaparinux: does it cause HIT? can it treat HIT?. <i>Expert Review of Hematology</i> , 2010, 3, 567-581.	1.0	81
338	Accuracy of a prediction model for heparin-induced thrombocytopenia (HIT): An analysis based on individual patient data. <i>Clinica Chimica Acta</i> , 2011, 412, 1521-1526.	0.5	5
339	Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). <i>Thrombosis Research</i> , 2011, 127, 345-348.	0.8	45

#	ARTICLE	IF	CITATIONS
340	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. <i>Thrombosis Research</i> , 2011, 128, 256-260.	0.8	35
341	Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 993-994.	1.8	81
342	Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). <i>Thrombosis and Haemostasis</i> , 2011, 106, 1197-1202.	1.8	44
343	Recent advances in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2011, 18, 315-322.	1.2	20
344	A Diagnosis of Heparin-Induced Thrombocytopenia with Combined Clinical and Laboratory Methods in Cardiothoracic Surgical Intensive Care Unit Patients. <i>Anesthesia and Analgesia</i> , 2011, 113, 697-702.	1.1	50
345	Diagnosing Heparin-Induced Thrombocytopenia in Cardiac Surgical Patients. <i>Anesthesia and Analgesia</i> , 2011, 112, 747-749.	1.1	5
347	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2498-2500.	1.9	150
348	Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 245-250.	0.7	25
349	HIT paradigms and paradoxes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 105-117.	1.9	88
350	Review of Continuing Education Course on Hemostasis. <i>Toxicologic Pathology</i> , 2011, 39, 281-288.	0.9	8
351	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Prävention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. <i>Laboratoriums Medizin</i> , 2011, 35, 45-54.	0.1	0
352	Rapid and simple IgG specific test for the exclusion of heparin induced thrombocytopenia (HIT). <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 2065-8.	1.4	10
353	Heparin-induced thrombocytopenia. <i>Journal of Emergencies, Trauma and Shock</i> , 2011, 4, 97.	0.3	10
354	Evaluating Heparin-Induced Thrombocytopenia: The Old and the New. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 135-143.	1.5	23
355	Heparin-Induced Thrombocytopenia: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 483-496.	1.5	49
356	Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 237-251.	1.1	39
357	A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2012, 115, 1273-1278.	1.1	16
358	Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. <i>Haematologica</i> , 2012, 97, 89-97.	1.7	63

#	ARTICLE	IF	CITATIONS
359	How I treat heparin-induced thrombocytopenia. <i>Blood</i> , 2012, 119, 2209-2218.	0.6	135
360	Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. <i>Blood</i> , 2012, 119, 5955-5962.	0.6	34
361	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	0.6	65
362	Adverse Effects of Heparin. <i>Handbook of Experimental Pharmacology</i> , 2012, , 211-263.	0.9	69
363	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2012, 120, 4160-4167.	0.6	393
364	CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. <i>Thrombosis Research</i> , 2012, 129, S97-S100.	0.8	15
366	Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. , 2012, , CD007557.		40
367	Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure. <i>Platelets</i> , 2012, 23, 495-498.	1.1	13
368	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT. <i>Thrombosis and Haemostasis</i> , 2012, 107, 575-583.	1.8	43
369	Management of heparin-induced thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 987-1006.	0.9	11
370	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2012, 141, e495S-e530S.	0.4	860
371	Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. <i>Clinical Research in Cardiology</i> , 2012, 101, 445-452.	1.5	3
372	Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 430-436.	1.9	12
373	A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1446-1449.	1.9	8
374	Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 1213-1218.	0.4	18
375	Interference of thrombin in immunological assays for hirudin specific antibodies. <i>Journal of Immunological Methods</i> , 2012, 381, 50-58.	0.6	4
376	Diagnosis and Management of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 541-563.	0.9	33
378	Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. <i>Thrombosis Research</i> , 2013, 132, 217-220.	0.8	20

#	ARTICLE	IF	CITATIONS
379	The skin and hypercoagulable states. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 450-462.	0.6	63
380	Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies. <i>International Journal of Hematology</i> , 2013, 98, 472-477.	0.7	2
381	Fc γ R1a proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1146-1153.	1.9	14
382	Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction. <i>Revista Da Associação Médica Brasileira</i> , 2013, 59, 161-166.	0.3	16
383	Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2013, 59, 161-166.	0.1	1
384	Thrombop \hat{e} nies induites par lâ€™™h \hat{e} parine. <i>Revue Francophone Des Laboratoires</i> , 2013, 2013, 51-59.	0.0	1
385	Deep Venous Thrombosis. <i>Journal of Radiology Nursing</i> , 2013, 32, 160-164.	0.2	0
386	Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2013, 368, 737-744.	13.9	107
388	Heparin-Induced Thrombocytopenia. <i>Methods in Molecular Biology</i> , 2013, 992, 301-318.	0.4	3
390	Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 208-214.	0.7	3
391	Heparin \hat{e} induced thrombocytopenia following hip and knee arthroplasty. <i>British Journal of Haematology</i> , 2013, 161, 255-261.	1.2	13
392	Heparin-Induced Thrombocytopenia: Pathophysiology, Diagnosis, and Treatment Monitoring. <i>Drug Development Research</i> , 2013, 74, 558-567.	1.4	1
393	Murine Monoclonal Antibody to Platelet Factor 4/Heparin Complexes as a Potential Reference Standard for Platelet Activation Assays in Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 37-41.	0.7	7
394	Novel diagnostic assays for heparin-induced thrombocytopenia. <i>Blood</i> , 2013, 121, 3727-3732.	0.6	41
395	Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2013, 109, 504-509.	1.8	5
398	Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 53-64.	1.8	67
399	Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. <i>Journal of Blood Medicine</i> , 2014, 5, 131.	0.7	24
400	Heparin Induced Thrombocytopenia. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
401	Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. <i>Thrombosis and Haemostasis</i> , 2014, 111, 862-872.	1.8	13
402	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1191-1193.	1.8	1
403	Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia: An Integrated Approach. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 106-114.	1.5	102
404	Ten-year screening for thrombocytopenia after aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 18, 562-567.	0.5	6
405	Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 587 Td (Exp Haematology, 2014, 166, 774-782.	1.2	41
406	Current insights into the laboratory diagnosis of HIT. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 296-305.	0.7	47
407	Anti-platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 871-878.	1.9	9
408	Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity. <i>BMC Structural Biology</i> , 2014, 14, 26.	2.3	21
409	Venous and Arterial Thrombosis. , 2014, , 277-296.		6
410	CalDAG-GEFI deficiency protects mice from Fc β RIIa-mediated thrombotic thrombocytopenia induced by CD40L and β 2GPI immune complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2113-2119.	1.9	23
414	Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients. <i>Thrombosis Research</i> , 2014, 134, 957-962.	0.8	4
415	Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. <i>Soft Matter</i> , 2014, 10, 2775.	1.2	15
416	Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing. <i>Thrombosis Research</i> , 2014, 134, 90-92.	0.8	2
417	Amplification of bacteria-induced platelet activation is triggered by Fc β RIIA, integrin α IIb β 3, and platelet factor 4. <i>Blood</i> , 2014, 123, 3166-3174.	0.6	126
418	The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia. <i>Transfusion</i> , 2015, 55, 1128-1134.	0.8	11
419	Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. <i>Blood</i> , 2015, 125, 155-161.	0.6	79
420	Prospective evaluation of automatized <sc>PF</sc>4/heparin immunoassays Hemos<sc>IL HIT</sc>-ab (<sc>PF</sc>4-H) for the diagnosis of heparin-induced thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 244-252.	0.7	13
421	Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true <sc>HIT</sc> (<sc>HIT</sc>-reactive antibodies) Tj ETQq1 1 0.784314 rgBT	1.0	14

#	ARTICLE	IF	CITATIONS
422	Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1900-1907.	1.9	78
423	Heparin-induced thrombocytopenia. <i>Current Opinion in Critical Care</i> , 2015, 21, 576-585.	1.6	47
424	Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test. <i>Journal of Blood Medicine</i> , 2015, 6, 277.	0.7	2
425	Over-testing for heparin induced thrombocytopenia in hospitalized patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 12-16.	1.0	20
426	Pharmacotherapy of heparin-induced thrombocytopenia: Therapeutic options and challenges in the clinical practices. <i>Journal of Vascular Nursing</i> , 2015, 33, 10-20.	0.2	5
427	Outcome of patients with positive heparin-platelet factor-4 antibodies: A retrospective multi-institutional observational study. <i>Platelets</i> , 2015, 26, 661-664.	1.1	2
428	Heparin-Induced Thrombocytopenia in Critically Ill Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 049-060.	1.5	87
429	Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 177-180.	0.7	3
430	Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. <i>Nanoscale</i> , 2015, 7, 10130-10139.	2.8	46
431	Deep Venous Thrombosis. , 2015, , 135-149.		0
432	Current management of heparin-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2015, 8, 837-849.	1.0	11
433	Novel HIT antibody detection method using Sonoclot® coagulation analyzer. <i>Thrombosis Research</i> , 2015, 135, 127-129.	0.8	2
434	Rivaroxaban in treatment refractory heparin-induced thrombocytopenia. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216110.	0.2	7
435	Vitrectomy for Proliferative Diabetic Retinopathy in a Patient with Heparin-Induced Thrombocytopenia. <i>Case Reports in Ophthalmology</i> , 2016, 7, 67-73.	0.3	2
436	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 823-834.	1.8	41
437	Role of monocytes and endothelial cells in heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 806-812.	1.8	15
438	Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1044-1055.	1.8	56
439	Management of the multiple phases of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 835-842.	1.8	43

#	ARTICLE	IF	CITATIONS
440	Safe bridging to warfarin in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 226-228.	0.8	0
441	Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 705-717.	0.5	21
442	Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 127, 464-472.	0.6	86
443	Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 546-557.	0.6	112
444	Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: Two case reports providing evidence for the role of preoperative LMWH in triggering sensitization. <i>Thrombosis Research</i> , 2016, 146, 126-130.	0.8	5
445	Bullous dermatosis at distant sites in patients treated with heparin. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.12	0.1	2
447	Thrombocytopenia. <i>Primary Care - Clinics in Office Practice</i> , 2016, 43, 543-557.	0.7	35
448	Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 813-822.	1.8	69
449	An update on heparin-induced thrombocytopenia: diagnosis and management. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 787-797.	1.0	10
450	A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. <i>Chest</i> , 2016, 150, 506-515.	0.4	80
452	Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 419-426.	1.5	11
454	Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1203-1212.	1.9	32
455	Heparin-induced thrombocytopenia. <i>Blood</i> , 2017, 129, 2864-2872.	0.6	319
456	Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. <i>The Cochrane Library</i> , 2017, 2017, CD007557.	1.5	64
457	Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 691-698.	1.5	48
458	Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 370-374.	1.9	15
459	Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved <i>Amblyomma americanum</i> tick saliva serpin 19. <i>Insect Biochemistry and Molecular Biology</i> , 2017, 80, 1-10.	1.2	27
460	PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. <i>Thrombosis Research</i> , 2017, 159, 39-47.	0.8	14

#	ARTICLE	IF	CITATIONS
461	A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. <i>Chest</i> , 2017, 152, e77-e80.	0.4	20
462	Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. <i>British Journal of Haematology</i> , 2017, 179, 811-819.	1.2	51
463	Implementation of a rapid HIT immunoassay at a university hospital – Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia. <i>Thrombosis Research</i> , 2017, 158, 65-70.	0.8	1
464	Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. <i>Platelets</i> , 2017, 28, 614-620.	1.1	51
465	Impact of pneumatic tube system transport for the monitoring of heparin therapy. <i>Thrombosis Research</i> , 2017, 158, 35-37.	0.8	1
466	HITs and misses in 100 years of heparin. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 667-673.	0.9	8
468	Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and FcγRIIA. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1187-1197.	1.9	64
469	Heparin-Induced Thrombocytopenia in the Critically Ill Patient. <i>Chest</i> , 2018, 154, 678-690.	0.4	26
470	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1402-1412.	1.9	8
471	Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 536-542.	1.0	4
472	Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	0.7	34
473	Anticoagulant-Free Off-Pump Left Ventricular Assist Device Implant. <i>Annals of Thoracic Surgery</i> , 2018, 105, e37-e39.	0.7	10
474	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3360-3392.	2.5	448
475	Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 294S-300S.	0.7	5
476	Hemostatic Abnormalities in the Critically Ill. , 2018, , 17-39.		0
477	An update on evidence based diagnostic and confirmatory testing strategies for heparin induced thrombocytopenia using combined immunological and functional assays. <i>Transfusion and Apheresis Science</i> , 2018, 57, 804-811.	0.5	7
478	Moving target PF4 directs HIT responses. <i>Blood</i> , 2018, 132, 678-679.	0.6	1
479	Hematologic Disorders. <i>Anesthesiology Clinics</i> , 2018, 36, 553-565.	0.6	4

#	ARTICLE	IF	CITATIONS
480	Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. <i>Perfusion (United Kingdom)</i> , 2018, 33, 1017-1021.	0.7	8
481	Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia. <i>Clinical Cardiology</i> , 2018, 41, 1521-1526.	0.7	8
482	Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. <i>Blood</i> , 2018, 132, 727-734.	0.6	9
483	High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. <i>Expert Review of Hematology</i> , 2019, 12, 685-698.	1.0	121
484	A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. <i>Platelets</i> , 2019, 30, 1017-1021.	1.1	6
485	Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2019, 119, 941-951.	1.8	9
487	Evaluation of heparin induced thrombocytopenia using probability scores in a mechanical circulatory support population. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 134-140.	1.0	8
488	Heparinoids Danaparoid and Sulodexide as clinically used drugs. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 163, 55-74.	0.9	19
490	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. <i>Blood</i> , 2019, 133, 978-989.	0.6	14
491	Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 389-399.	1.9	33
493	The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT). <i>Transfusion Medicine Reviews</i> , 2020, 34, 34-41.	0.9	4
494	Thrombocytopenia and thrombocytosis. , 2020, , 695-719.		1
495	Serotonin release assay-negative heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2020, 95, 38-47.	2.0	43
496	Measurement of blood activation markers applied to the early diagnosis of cardiovascular alterations. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 85-98.	1.5	3
497	Extracellular DNA: A Danger Signal Triggering Immunothrombosis. <i>Frontiers in Immunology</i> , 2020, 11, 568513.	2.2	33
498	Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. <i>Hamostaseologie</i> , 2020, 40, 472-484.	0.9	11
499	SARS-CoV-2 and pulmonary embolism: who stole the platelets?. <i>Thrombosis Journal</i> , 2020, 18, 16.	0.9	11
500	<p><p>Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 267-277.	0.7	15

#	ARTICLE	IF	CITATIONS
501	Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics. <i>Biomacromolecules</i> , 2020, 21, 2595-2621.	2.6	7
502	Evolving concepts of pathogenesis of heparin-induced thrombocytopenia: Diagnostic and therapeutic implications. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 25-32.	0.7	13
503	Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1362-1366.	1.0	11
504	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1096-1107.	1.8	29
505	Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia. , 0, , .		3
506	Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation. <i>Thrombosis Research</i> , 2020, 188, 52-60.	0.8	11
507	The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2020, 194, 135-141.	0.8	5
508	Bleeding, Heparin-induced thrombocytopenia, and Other adverse reactions. , 2020, , 147-187.		0
509	Diagnosis and management of heparin-induced thrombocytopenia. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 291-310.	0.6	45
510	Factors influencing activated clotting time following heparin administration for the initiation of cardiopulmonary bypass. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 38-43.	0.4	5
511	Construction of heparan sulfate microarray for investigating the binding of specific saccharide sequences to proteins. <i>Glycobiology</i> , 2021, 31, 188-199.	1.3	16
512	Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys. <i>MAbs</i> , 2021, 13, 1887628.	2.6	8
513	Intraoperative collection of autologous platelet-rich plasma from the cardiopulmonary bypass circuit upon initiation of extracorporeal circulation. <i>Journal of Cardiothoracic Surgery</i> , 2021, 16, 17.	0.4	0
514	An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia. <i>Biomedicines</i> , 2021, 9, 296.	1.4	6
515	Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. <i>Expert Review of Hematology</i> , 2021, 14, 335-346.	1.0	12
516	Heparin-induced thrombocytopenia. <i>Cmaj</i> , 2021, 193, E736-E736.	0.9	29
517	Understanding VITT(ual) reality. <i>Blood</i> , 2021, 138, 285-286.	0.6	2
518	P-selectin expression assay in a repeatedly serotonin-release assay-negative patient with heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2021, Publish Ahead of Print, 522-525.	0.5	1

#	ARTICLE	IF	CITATIONS
519	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. <i>Thrombosis Research</i> , 2021, 204, 40-51.	0.8	72
520	Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12581.	1.0	5
521	Heparin-induced Thrombocytopenia Diagnosis: A Retrospective Study Comparing Heparin-induced Platelet Activation Test to 14C-serotonin Release Assay. <i>TH Open</i> , 2021, 05, e507-e512.	0.7	5
523	<i>Hematologic Emergencies.</i> , 2022, , 121-145.		0
524	<i>Immunology of Leucocytes, Platelets and Plasma Components.</i> , 0, , 546-610.		1
525	Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia. <i>Methods in Molecular Biology</i> , 2010, 663, 133-156.	0.4	3
526	<i>Heparin-induzierte Thrombozytopenie.</i> , 1999, , 83-94.		1
527	<i>Transfusion Medicine and Coagulation Disorders.</i> , 2011, , 949-991.		3
528	The molecular basis of immune-based platelet disorders. <i>Clinical Science</i> , 2020, 134, 2807-2822.	1.8	1
531	Heparin-Associated Thrombocytopenia: The Effects of Various Intravenous IgG Preparations on Antibody Mediated Platelet Activation - A Possible New Indication for High Dose i.v. IgG. <i>Thrombosis and Haemostasis</i> , 1994, 71, 641-645.	1.8	81
532	Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 1995, 74, 886-892.	1.8	139
533	Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases. <i>Thrombosis and Haemostasis</i> , 1995, 73, 021-028.	1.8	243
535	Prevalence and Persistence of Heparin/Platelet Factor 4 Antibodies in Patients with Heparin Coated and Noncoated Ventricular Assist Devices. <i>ASAIO Journal</i> , 2000, 46, 319-322.	0.9	39
536	THE "WHITE CLOT SYNDROME" IN HEPATIC TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 982-984.	0.5	7
537	INHIBITOR AGAINST COAGULATION FACTOR V AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1999, 68, 1054-1056.	0.5	20
538	NEW APPROACH FOR DETECTION OF HEPARIN DEPENDENT ANTIBODIES AND RISK ASSESSMENT FOR HEPARIN INDUCED THROMBOCYTOPENIA. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, P-T-319-P-T-319.	1.9	2
539	Management of Deep Vein Thrombosis and Pulmonary Embolism. <i>Circulation</i> , 1996, 93, 2212-2245.	1.6	553
540	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. <i>Circulation</i> , 1997, 95, 1242-1246.	1.6	293

#	ARTICLE	IF	CITATIONS
541	Relationship between Platelet Aggregatory and Heparin-Induced Thrombocytopenia Type II. Science Research, 2014, 2, 78.	0.2	1
542	Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.. Journal of Clinical Investigation, 1994, 93, 81-88.	3.9	504
543	Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. Journal of Clinical Investigation, 2017, 127, 1090-1098.	3.9	37
544	Drug-Induced Thrombophilic or Prothrombotic States: An Underestimated Clinical Problem That Involves Both Legal and Illegal Compounds. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 775-785.	0.7	14
546	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the Fc γ RIIa-R-H131 Polymorphism. Blood, 1998, 92, 1526-1531.	0.6	3
547	Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia. Blood, 1998, 92, 3250-3259.	0.6	7
548	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood, 2000, 96, 188-194.	0.6	10
549	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	0.6	22
550	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood, 2000, 96, 2373-2378.	0.6	1
552	Role of Sulfated Polysaccharides in the Pathogenesis of Heparin- Induced Thrombocytopenia. , 2003, , .		7
553	Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-Hirudin, Expressed in Pichia pastoris, for NMR Studies. PLoS ONE, 2012, 7, e42207.	1.1	9
554	Endovascular Repair of an Extracranial Internal Carotid Artery Aneurysm Complicated by Heparin-Induced Thrombocytopenia and Thrombosis. Journal of Endovascular Therapy, 2000, 7, 353-358.	0.8	8
555	Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematology, 2009, 25, 125-135.	0.2	41
556	New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 87-91.	0.4	8
557	Open-heart surgery in a patient with severe heart failure with heparin-induced thrombocytopenia. Chirurgia (Turin), 2020, 33, .	0.0	1
558	Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay. Blood Transfusion, 2021, 19, 77-84.	0.3	2
559	Heparin-Induced Thrombocytopenia and Treatment with Thrombin Inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2005, 16, 623-640.	0.1	2
560	History of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 1-20.	0.0	2

#	ARTICLE	IF	CITATIONS
561	Nonimmune Heparin-Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 117-130.	0.0	3
562	Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 131-148.	0.0	1
563	Role of Sulfated Polysaccharides in the Pathogenesis of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 167-186.	0.0	4
564	Platelet and Leukocyte Fc β 3 Receptors in Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 187-208.	0.0	3
565	Laboratory Testing for Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 227-260.	0.0	17
566	Pathophysiology of Heparin-Induced Thrombocytopenia. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1657-1666.	1.2	58
567	Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 1415-1423.	1.2	124
568	Investigations of the Immunoglobulin Subtype Transformation of Anti-Heparin-Platelet Factor 4 Antibodies During Treatment With a Low-Molecular-Weight Heparin (Clivarin) in Orthopedic Patients. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 584-588.	1.2	13
569	Dabigatran use after argatroban for heparin-induced thrombocytopenia with thrombosis: A case series and literature review. <i>Annals of Vascular Surgery</i> , 2021, , .	0.4	1
570	Lupus Anticoagulants: Mechanistic and Diagnostic Considerations. , 2000, , 225-237.		0
571	Principles in Hemostasis. , 2000, , 1201-1223.		0
573	Venous Disease and Pulmonary Embolism. , 2001, , 1083-1109.		0
574	ãf~ãf'ãf'ãf'ãf'3èµ.ã>æ€Sè;€ã°æ¿æ¿ã°ç—†ã®æœæÿ»ã®è°æ—. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2002, 113, 284-288.		
575	ãf~ãf'ãf'ãf'ãf'3èµ.ã>æ€Sè;€ã°æ¿æ¿ã°ç—†ã®ãf~ãf'ãf'ãf'ãf'3ãf»PF4è†ã½“æŠ—ã½“ã®æã†°æ³•ã®ç¾4æ³•. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2002, 113, 284-288.		
576	Zur Problematik des akuten arteriellen Verschlusses als Folge einer heparininduzierten Thrombozytopenie. <i>Berliner GefÄsschirurgische Reihe</i> , 2002, , 69-77.	0.0	0
577	A case of heparin-induced thrombocytopenia with multiple thrombosis concomitant with various allergic manifestations.. <i>Nihon Toseki Igakkai Zasshi</i> , 2003, 36, 1343-1348.	0.2	0
578	Anticoagulant therapy. , 2003, , 157-165.		0
581	A case with combined multiple retina thrombosis probably due to heparin-induced thrombocytopenia (HIT). <i>Nihon Toseki Igakkai Zasshi</i> , 2004, 37, 1437-1442.	0.2	0

#	ARTICLE	IF	CITATIONS
583	Heparin Induced Thrombocytopenia. , 2007, , 1-4.		0
586	Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 149-166.	0.0	1
587	Venous Disease and Pulmonary Embolism. , 2008, , 1429-1456.		1
588	Heparin-induced Thrombocytopenia (HIT)(1. Systemic Complications Neurosurgeons need to) Tj ETQq1 1 0.784314 rgBT /Overlock 100T 2008, 17, 909-916.	0.0	1
589	Heparin-induced Thrombocytopenia (HIT). Nosotchu, 2008, 30, 960-966.	0.0	1
590	Improving Blood Compatibility of Biomaterials Using a Novel Antithrombin-Heparin Covalent Complex. , 2008, , 535-572.		0
592	HIT-Diagnostik. , 2010, , 857-860.		0
593	Hematologic Disorders in the Elderly. , 2011, , 207-219.		0
594	Heparin-induced thrombocytopenia type II in a patient who underwent rectal cancer surgery. Nihon Daicho Komonbyo Gakkai Zasshi, 2012, 65, 26-30.	0.1	0
596	Recent advances in the pathogenesis, diagnosis, and treatment of immune heparin-induced thrombocytopenia. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 362-374.	0.1	3
598	Why Is the Platelet Count Low: Should I Be Concerned About Heparin-Induced Thrombocytopenia?. Journal of Pediatric Pharmacology and Therapeutics, 2012, 17, 2-6.	0.3	12
599	Murine models of heparin-induced thrombocytopenia. , 2012, , 264-283.		0
600	Heparin-induced thrombocytopenia (HIT) in hemodialysis patients experienced in our hospital. Nihon Toseki Igakkai Zasshi, 2013, 46, 1075-1081.	0.2	0
603	Thrombocytopenia in the Intensive Care Unit and After Solid Organ Transplantation. , 2014, , 115-132.		1
604	Coagulation in Kidney Disease. , 2014, , 603-612.		0
605	Early Graft Dysfunction Post Coronary Artery Bypass due to Heparin Induced Thrombocytopenic Thrombosis. IOSR Journal of Dental and Medical Sciences, 2014, 13, 13-16.	0.0	0
606	Hematologic Complications of Transplantation. , 2014, , 235-245.		0
607	Äkute GefÄÄverschlÄÄsse â€” interdisziplinÄres Therapiespektrum. , 1995, , 1030-1066.		0

#	ARTICLE	IF	CITATIONS
608	Die Heparin-induzierte Thrombozytopenie. , 1996, , 71-77.		0
609	Heparin-associated Autoantibodies. , 1996, , 343-350.		0
610	Heparin as a cause of thrombus progression. European Journal of Pediatrics, 1996, 155, 11-14.	1.3	30
612	HÄmostaseologie und Einflusfaktoren auf Entstehung und Verlauf von GefÄÄkrankheiten. , 1997, , 57-67.		0
614	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. Blood, 1998, 91, 549-554.	0.6	0
615	Platelet Fc receptors for IgG and IgE. , 1998, , 119-134.		1
616	Antibodies From Patients With Heparin-Induced Thrombocytopenia/Thrombosis Recognize Different Epitopes on Heparin: Platelet Factor 4. Blood, 1998, 91, 916-922.	0.6	0
617	Early Onset of Immunological Heparin-Induced Thrombocytopenia in Acute Myocardial Infarction and Anti-Platelet Factor 4-Heparin Complex Antibody.. Japanese Journal of Thrombosis and Hemostasis, 1999, 10, 106-110.	0.1	0
618	Pathophysiologie und Therapie der heparininduzierten Thrombozytopenie: Warum sind Antikoagulanzen mit AntithrombinaktivitÄt sinnvoll bei HIT?. , 1999, , 101-115.		0
619	Heparin and Other Indirect Antithrombin Agents. Handbook of Experimental Pharmacology, 1999, , 259-303.	0.9	0
621	Anticoagulant Managements of Left Ventricular Assist Device Implantation in Two Patients with Heparin-Induced Thrombocytopenia (HIT): Use of Argatroban as an Anticoagulant for Cardiopulmonary Bypass. Journal of Anesthesia & Clinical Research, 2015, 06, .	0.1	0
622	Heparin-Induced Thrombocytopenia: Diagnosis and Management. , 2016, , 519-529.		0
623	Treatment of Heparin-Induced Thrombocytopenia. , 2016, , 291-310.		1
624	Risk factors for venous thromboembolism in women. Reproductive Endocrinology, 2018, .	0.0	0
625	Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. American Journal of Case Reports, 2020, 21, e922498.	0.3	2
626	Platelet antibodies in immune thrombocytopenia and related conditions. Journal of Laboratory Medicine, 2020, 44, 273-284.	1.1	7
627	Argatroban as Purge Solution in Patients With Heparin-Induced Thrombocytopenia on an Impella Device, a Case Review. American Journal of Therapeutics, 2020, Publish Ahead of Print, e763-e765.	0.5	4
630	The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector-based COVID-19 vaccination: Where there is much light, the shadow is deep. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12609.	1.0	1

#	ARTICLE	IF	CITATIONS
631	Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 975-988.	1.9	17
632	Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 3114-3125.	2.5	1
634	Platelet-activating anti-PF4 disorders: An overview. <i>Seminars in Hematology</i> , 2022, 59, 59-71.	1.8	25
635	Laboratory testing for VITT antibodies. <i>Seminars in Hematology</i> , 2022, 59, 80-88.	1.8	11
636	Similarities of antiphospholipid antibodies in HIT and APS patients with heparin-platelet factor 4 antibodies. <i>Thrombosis Update</i> , 2022, , 100106.	0.4	0
637	Rare presentation of enoxaparin-induced skin necrosis in a postoperative patient. <i>BMJ Case Reports</i> , 2022, 15, e249685.	0.2	3
638	A Case of Heparin-induced Thrombocytopenia after Surgery for Esophageal Cancer. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2021, 46, 120-125.	0.0	0
639	The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4228-4235.	2.5	18
640	Reducing Delayed Diagnosis and Overtreatment in Heparin-Induced Thrombocytopenia by Using a Machine-Learning Model: A Prospective, Multicenter, Observational Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
641	Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. <i>Cells</i> , 2022, 11, 3214.	1.8	17
642	Vaccine-induced immune thrombotic thrombocytopenia: Updates in pathobiology and diagnosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
643	A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study. <i>EClinicalMedicine</i> , 2023, 55, 101745.	3.2	8
644	Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 621-633.	1.5	12
645	Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 444-452.	1.5	6
646	Functional Testing for Heparin-Induced Thrombocytopenia Using Whole Blood Multiplate Impedance Aggregometry. <i>Methods in Molecular Biology</i> , 2023, , 417-428.	0.4	0
647	Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing. <i>Methods in Molecular Biology</i> , 2023, , 441-461.	0.4	1